EurekaMag.com logo
+ Site Statistics
References:
53,214,146
Abstracts:
29,074,682
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

4-Hydroxyandrostenedione: A new treatment for postmenopausal patients with breast cancer



4-Hydroxyandrostenedione: A new treatment for postmenopausal patients with breast cancer



European Journal of Cancer 28A(12): 1941-1945



We have evaluated 4-hydroxyandrostenedione, a specific inhibitor of aromatase, as treatment for breast cancer in a phase I dose-ranging study and a phase II study of the best-tolerated dose. 168 postmenopausal patients with locally advanced and metastatic breast cancer were treated intramuscularly. 19% of patients attained a complete or partial response but 26% of those who completed at least 4 weeks treatment responded. Side-effects were least in the group receiving 250 mg every 2 weeks. 13% of patients experienced local discomfort due to the injection and 5% had other side-effects. Serum oestradiol fell to 42.4 and 26.5% of baseline at 7 days after the start of treatment with the 250 mg and 500 mg dose, respectively. We conclude that 4-hydroxyandrostenedione at 250 mg every 2 weeks is a safe and effective form of treatment for postmenopausal patients with metastatic breast cancer.

Accession: 008016584

Download citation: RISBibTeXText

PMID: 1419285

DOI: 10.1016/0959-8049(92)90232-Q

Download PDF Full Text: 4-Hydroxyandrostenedione: A new treatment for postmenopausal patients with breast cancer



Related references

4-Hydroxyandrostenedione treatment for postmenopausal patients with breast cancer. Journal of Steroid Biochemistry and Molecular Biology 43(1-3): 145-148, 1992

4-Hydroxyandrostenedione treatment for postmenopausal patients with advanced breast cancer. Steroids 50(1-3): 245-252, 1987

4-Hydroxyandrostenedione in treatment of postmenopausal patients with advanced breast cancer. Lancet 2(8414): 1237-1239, 1984

Treatment of metastatic breast cancer mbc in postmenopausal patients with 4 hydroxyandrostenedione 4 oha cgp 32 349. Journal of Cancer Research & Clinical Oncology 116(SUPPL PART 1): 395, 1990

Efficacy and tolerability of 4-hydroxyandrostenedione as first-line treatment in postmenopausal patients with breast cancer after adjuvant therapy. Cancer Treatment Reviews 19(SUPPL B): 31-36, 1993

Efficacy and tolerability of 4-hydroxyandrostenedione (4-OHA) as first-line treatment in postmenopausal patients with breast cancer after adjuvant therapy. Cancer Treatment Reviews 19 Suppl B: 31-36, 1993

Aromatase inhibition with 4-hydroxyandrostenedione in the treatment of postmenopausal patients with advanced breast cancer: a phase II study. Journal of Clinical Oncology 8(5): 875-880, 1990

Treatment of advanced breast cancer in postmenopausal women with 4-hydroxyandrostenedione. Cancer ChemoTherapy and Pharmacology 26(1): 75-78, 1990

Endocrine pharmacology of oral 4 hydroxyandrostenedione in postmenopausal breast cancer patients. Journal of Endocrinology 123(SUPPL): 153, 1989

Endocrine effects of the suicide substrate 4 hydroxyandrostenedione in postmenopausal breast cancer patients. Journal of Endocrinology 104(SUPPL): 28, 1985

Endocrinology and pharmacokinetics of oral 4 hydroxyandrostenedione in postmenopausal patients with advanced breast cancer. Steroids6: 615-616, 1987

Treatment of advanced postmenopausal breast cancer with an aromatase inhibitor, 4-hydroxyandrostenedione: phase II report. Cancer Research 46(9): 4823-4826, 1986

Endocrine pharmacokinetic studies of aromatase inhibitor 4 hydroxyandrostenedione in postmenopausal breast cancer patients. Uicc (Union Internationale Contre Le Cancer, International Union Against Cancer) 14th International Cancer Congress, Budapest, Hungary, Aug 21-27, Abstracts, Lectures, Symposia And Free Communications, Vols 1, 2, 3, Late Abstracts, And Register Xvi+479p (Vol 1); Xvi+298p (Vol 2); Xvi+531p (Vol 3); 15p (Late Abstracts); 40p (Register) S Karger Ag: Basel, Switzerland; New York, N Y , Usa; Akademiai Kiado: Budapest, Hungary Paper 1102, 1986

Dose-related endocrine effects and pharmacokinetics of oral and intramuscular 4-hydroxyandrostenedione in postmenopausal breast cancer patients. Cancer Research 49(5): 1306-1312, 1989